Johnson & Johnson Enterprise Innovation Inc.
Clinical trials sponsored by Johnson & Johnson Enterprise Innovation Inc., explained in plain language.
A subsidiary of Johnson & Johnson focused on innovation and partnerships.
Not investment advice. Company information is shown for context only. Clinical trials frequently fail.
Advertising disclosure. Links marked "(ad)" go to partners we have a commercial relationship with, either a broker where you can trade or a stock-research service, and we may earn a commission if you open an account or subscribe. This never affects what is shown here.
Upcoming readouts
Trials from this sponsor expected to report results within the next 12 months.
- New drug combo aims to boost lung cancer treatment Results expected Apr 2027 (estimated)
-
Nanoparticles boost radiation to fight head and neck cancer in elderly
Disease control Recruiting nowThis phase 3 trial tests whether injecting NBTXR3 nanoparticles into tumors before radiation therapy can improve outcomes for elderly patients with advanced head and neck cancer who cannot receive chemotherapy. About 500 participants will be randomly assigned to receive either ra…
Phase 3 • Sponsor: Johnson & Johnson Enterprise Innovation Inc. • Aim: Disease control
Last updated Aug 30, 2026 00:00 UTC
-
New chemo injection targets tumors directly in early trial
Disease control Recruiting nowThis early-stage study tests a chemotherapy drug (JNJ-1761981) that is injected directly into tumors in people with solid cancers that have not responded to standard treatments. The goal is to find a safe and effective dose, and to see if adding an immunotherapy (cetrelimab) help…
Phase 1 • Sponsor: Johnson & Johnson Enterprise Innovation Inc. • Aim: Disease control
Last updated Aug 30, 2026 00:00 UTC
-
New injection plus chemo-radiation targets tough head and neck tumors
Disease control Recruiting nowThis early-stage study is testing whether a new drug, JNJ-90301900, is safe and works when injected directly into tumors along with standard chemotherapy and radiation. It involves 30 adults with advanced head and neck cancer. The main goal is to check for side effects and see ho…
Phase 1 • Sponsor: Johnson & Johnson Enterprise Innovation Inc. • Aim: Disease control
Last updated Aug 30, 2026 00:00 UTC
-
Cancer-Fighting virus injected into tumors shows promise in early trial
Disease control Recruiting nowThis early-phase study tests a virus (JNJ-87704916) that is injected directly into tumors to kill cancer cells. It is being tested alone and with another drug (cetrelimab) in people with advanced solid tumors who have run out of standard treatments. The main goals are to check sa…
Phase 1 • Sponsor: Johnson & Johnson Enterprise Innovation Inc. • Aim: Disease control
Last updated Aug 30, 2026 00:00 UTC
-
New hope for stage III lung cancer? trial adds experimental drug to standard care
Disease control Recruiting nowThis study tests whether adding an experimental drug (JNJ-90301900) to standard chemoradiation and a follow-up immunotherapy (durvalumab) can shrink tumors more effectively in people with locally advanced, inoperable stage III non-small cell lung cancer. About 130 participants wi…
Phase 2 • Sponsor: Johnson & Johnson Enterprise Innovation Inc. • Aim: Disease control
Last updated Aug 30, 2026 00:00 UTC